GlaxoSmithKline PLC Result of General Meeting (1952A)

TIDMGSK

RNS Number : 1952A

GlaxoSmithKline PLC

18 December 2014

Issued: Thursday 18 December 2014, London UK - LSE Announcement

Result of General Meeting relating to the proposed major transaction with Novartis

GlaxoSmithKline plc (GSK) announces that at its General Meeting held earlier today, the sole resolution was passed by shareholders by an overwhelming majority. As previously announced, the transaction is expected to complete during the first half of 2015, subject to approvals.

GlaxoSmithKline General Meeting Poll Results

The following table shows the votes cast in respect of the resolution:

 
   Resolution        Total votes       %   Total votes      %     Total votes           Votes 
                          for(*)               against                   cast    withheld(**) 
 Proposed major 
  transaction 
  with Novartis 
  AG               3,606,194,474   99.79   7,672,471     0.21   3,613,866,945   11,617,644 
                  --------------  ------  ------------  -----  --------------  -------------- 
 

In accordance with Listing Rule 9.6.2, a copy of the resolution will be submitted to the UK Listing Authority and will in due course be available for inspection at www.morningstar.co.uk/uk/NSM.

Notes:

   *           Includes discretionary votes. 

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

The following table provides further relevant information:

 
 Issued share capital 
  (excluding Treasury Shares)         4,863,747,114 
 Total votes cast and votes 
  withheld lodged as a % of 
  GSK's issued share capital 
  (excluding Treasury Shares)             74.54 
                                     -------------- 
 Total shareholder population            139,567 
                                     -------------- 
 Total number of proxies lodged          12,457 
                                     -------------- 
 % of shareholders who lodged 
  proxies                                 8.93 
                                     -------------- 
 Number of shareholders, corporate 
  representatives and proxies 
  who attended the General Meeting         75 
                                     -------------- 
 

V A Whyte

Company Secretary

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 
 GSK enquiries: 
 UK Media enquiries:   David Mawdsley    [phone]    (London) 
                                          5502 
                       Simon Steel       [phone]    (London) 
                                          5502 
                       Sarah Spencer     + 44 (0) 20 8047   (London) 
                                          5502 
 
 US Media enquiries:   Stephen Rea       [phone]    (Philadelphia) 
                       Sarah Alspach     [phone]    (Washington) 
                       Mary Anne Rhyne   [phone]    (North Carolina) 
 
 Analyst/Investor      Ziba Shamsi       [phone]    (London) 
  enquiries:                              3289 
                       Tom Curry         + 1 215 751 5419   (Philadelphia) 
                       Gary Davies       [phone]    (London) 
                                          5503 
                       James Dodwell     [phone]    (London) 
                                          2406 
                       Jeff McLaughlin   [phone]    (Philadelphia) 
 
 
 Information regarding forward-looking statements 
 
  This announcement includes statements that are, or may be deemed 
  to be, "forward-looking statements". These forward-looking statements 
  can be identified by the use of forward-looking terminology, 
  including the terms "believes", "estimates", "plans", "projects", 
  "anticipates", "expects", "intends", "may", "will", or "should" 
  or, in each case, their negative or other variations or comparable 
  terminology, or by discussions of strategy, plans, objectives, 
  goals, future events or intentions. These forward-looking statements 
  include all matters that are not historical facts. They appear 
  in a number of places throughout this announcement and include, 
  but are not limited to, statements regarding GSK's intentions, 
  beliefs or current expectations concerning, among other things, 
  GSK's business, results of operations, financial position, prospects, 
  growth, strategies and the industry in which it operates as 
  well as those of the Novartis businesses that are the subject 
  of the transaction. By their nature, forward-looking statements 
  involve risk and uncertainty because they relate to future events 
  and circumstances. Forward-looking statements are not guarantees 
  of future performance and the actual results of GSK's operations 
  and financial position, and the development of the markets and 
  the industry in which GSK operates, may differ materially from 
  those described in, or suggested by, the forward-looking statements 
  contained in this announcement. The same applies in respect 
  of the Novartis Businesses that are the subject of the transaction. 
  In addition, even if the results of operations, financial position 
  and the development of the markets and the industry in which 
  GSK operates are consistent with the forward-looking statements 
  contained in this announcement, those results or developments 
  may not be indicative of results or developments in subsequent 
  periods. A number of factors could cause results and developments 
  to differ materially from those expressed or implied by the 
  forward-looking statements including, without limitation, general 
  economic and business conditions, industry trends, competition, 
  changes in regulation, currency fluctuations, changes in its 
  business strategy, political and economic uncertainty and other 
  factors discussed in this announcement. 
 
  Forward-looking statements may, and often do, differ materially 
  from actual results. Any forward-looking statements in this 
  announcement speak only as of their respective dates, reflect 
  GSK's current view with respect to future events and are subject 
  to risks relating to future events and other risks, uncertainties 
  and assumptions relating to GSK's operations, results of operations 
  and growth strategy. You should specifically consider the factors 
  identified in this document, in addition to the risk factors 
  that may affect GSK's operations which are described under "Risk 
  Factors" in the Company's 2013 Annual Report on Form 20-F, which 
  could cause actual results to differ before making any decision 
  in relation to the Transaction as well as those of the Novartis 
  businesses that are the subject of the transaction. Subject 
  to the requirements of the FCA, the London Stock Exchange, the 
  Listing Rules and the Disclosure and Transparency Rules (and/or 
  any regulatory requirements) or applicable law, GSK explicitly 
  disclaims any obligation or undertaking publicly to release 
  the result of any revisions to any forward-looking statements 
  in this announcement that may occur due to any change in GSK's 
  expectations or to reflect events or circumstances after the 
  date of this announcement. 
 
 
 Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

REGLLFSFFRLTLIS